
Vor Biopharma Inc. (VOR) Stock Ticker
VOR right now
Market factors today
Unlock the full VOR picture
About Vor Biopharma Inc.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
VOR stock facts
| Ticker symbol | VOR |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.0B |
| CEO | Jean-Paul Kress |
| Employees | 76 |
| Headquarters | Boston, MA, US |
| IPO date | 2021-02-05 |
| Website | www.vorbio.com |
What you can see for VOR on Tickr
Live VOR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VOR report.
Rankings
FAQ
What is the ticker symbol for Vor Biopharma Inc.?
The ticker symbol for Vor Biopharma Inc. is VOR, listed on the NASDAQ Global Select.
What is VOR?
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature…